LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Abierto

SectorSanidad

21.57 -1.69

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.39

Máximo

22.02

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.588 50.102
BPA	0.47
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+55.9% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-45M 1.7B
Apertura anterior	23.26
Cierre anterior	21.57

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

121 / 344 Clasificación en Healthcare

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 may 2026, 22:47 UTC

Ganancias

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 may 2026, 20:45 UTC

Ganancias

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 may 2026, 23:39 UTC

Charlas de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 may 2026, 23:31 UTC

Charlas de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 may 2026, 23:17 UTC

Charlas de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 may 2026, 23:02 UTC

Charlas de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 may 2026, 22:37 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 may 2026, 21:12 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 may 2026, 21:00 UTC

Ganancias

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 may 2026, 20:57 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:55 UTC

Ganancias

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

28 may 2026, 20:48 UTC

Acciones populares

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 may 2026, 20:34 UTC

Ganancias

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 may 2026, 20:31 UTC

Ganancias

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 may 2026, 20:28 UTC

Ganancias

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 may 2026, 20:26 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Membership Fees $1.37B

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Net Sales $69.15B

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

55.9% repunte

Estimación a 12 Meses

Media 34.5 USD 55.9%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

121 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.